Middle East & Africa Antidiabetics Market Size & Outlook
Middle East & Africa antidiabetics market, 2018-2030 (US$M)
Related Markets
MEA antidiabetics market highlights
- The MEA antidiabetics market generated a revenue of USD 2,312.6 million in 2023.
- The market is expected to grow at a CAGR of 5.9% from 2024 to 2030.
- In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2023.
- GLP-1 Receptor Agonists is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 2,312.6 million |
| Market revenue in 2030 | USD 3,454.1 million |
| Growth rate | 5.9% (CAGR from 2023 to 2030) |
| Largest segment | Glp-1 receptor agonists |
| Fastest growing segment | GLP-1 Receptor Agonists |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Others Drug Class, Insulin |
| Key market players worldwide | AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.2% of the global antidiabetics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 18,852.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antidiabetics Market Scope
Antidiabetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa antidiabetics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antidiabetics market will help companies and investors design strategic landscapes.
Glp-1 receptor agonists was the largest segment with a revenue share of 35.34% in 2023. Horizon Databook has segmented the Middle East & Africa antidiabetics market based on glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors, others drug class, insulin covering the revenue growth of each sub-segment from 2018 to 2030.
- Middle East & Africa Antidiabetics Drug Class Outlook (Revenue, USD Million, 2018-2030)
- GLP-1 Receptor Agonists
- DPP- 4 Inhibitors
- SGLT2 Inhibitors
- Others Drug Class
- Insulin
- Long-acting insulin
- Premix insulin
- Fast-acting insulin
- Human insulin
- Middle East & Africa Antidiabetics Diabetes Type Outlook (Revenue, USD Million, 2018-2030)
- Type 1
- Type 2
- Middle East & Africa Antidiabetics Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Middle East & Africa Antidiabetics Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Oral
- Subcutaneous
- Intravenous
Reasons to subscribe to Middle East & Africa antidiabetics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa antidiabetics market databook
-
Our clientele includes a mix of antidiabetics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa antidiabetics market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa antidiabetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA antidiabetics market size, by country, 2018-2030 (US$M)
Middle East & Africa Antidiabetics Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
